Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.
September 06, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics and maintained a $3 price target, indicating confidence in the company's potential growth.
The reiteration of a Speculative Buy rating and maintenance of a $3 price target by Benchmark suggests positive sentiment and potential upside for UNCY, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100